Herbert Lancashire Dupont MD

Infectious Disease•Houston, TX

Clinical Professor, Infectious Disease, Baylor College of Medicine

Join to View Full Profile

6720 Bertner Ave# 1-164Houston, TX 77030
Phone+1 832-355-4122
Fax+1 832-355-4167

Education & Training

University of MarylandFellowship, Infectious Disease, 1968 - 1969
University of MinnesotaResidency, Internal Medicine, 1965 - 1967
Emory University School of MedicineClass of 1965

Certifications & Licensure

TX State Medical License 1973 - 2026
GA State Medical License 1965 - 1987
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
Elected Member The American Society for Clinical Investigation, 1980
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Start of enrollment: 2004 Jun 01
Completed
Phase 4
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Start of enrollment: 2004 Jan 01
Completed
Phase 3
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Start of enrollment: 2006 Jul 20
Completed
Phase 2
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea Start of enrollment: 2006 Aug 01
Completed
Phase 3
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis Start of enrollment: 2004 Jan 01
Completed
Phase 2
ETEC Logistics Trial (TREK) Start of enrollment: 2006 May 01
Completed
Phase 2
Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea Start of enrollment: 2008 Oct 01
Completed
Phase 4
Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study Start of enrollment: 2009 Oct 01
Completed
Phase 3
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients Start of enrollment: 2017 Jul 15
Withdrawn
Phase 1, Phase 2
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI) Start of enrollment: 2017 Dec 21
Terminated
Phase 2
Study of the Fecal Microbiome in Patients With Parkinson's Disease Start of enrollment: 2019 May 15
Completed
Phase 1
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
Available
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease Start of enrollment: 2023 Dec 01
Withdrawn
Phase 2
Roles: Principal Investigator, Contact
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis Start of enrollment: 2020 Sep 14
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis Start of enrollment: 2023 Dec 15
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

4 citations
Norovirus acute gastroenteritis amongst US and European travellers to areas of moderate to high risk of travellers' diarrhoea: a prospective cohort study.
Martin Alberer, Christine L Moe, Christoph Hatz, Kerstin Kling, Amy E Kirby
Journal of Travel Medicine. 2024-10-19
2 citations
Microbiota restoration therapies for recurrentinfection reach an important new milestone.
Herbert L DuPont, Andrew W DuPont, Glenn S Tillotson
Therapeutic Advances in Gastroenterology. 2024-01-01
2 citations
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.
Herbert L DuPont
Clinical Microbiology Reviews. 2023-12-20

Lectures

American College of Physicians: Delaware Chapter 14th Annual Lower Shores Symposia
American College of Physicians, Rehoboth Beach, Delaware - 10/27/2012

Press Mentions

Houstonians Honor Health Heroes and Raise $450,000 for Game-Changing Medical ResearchOctober 23rd, 2018
Avoid Foodborne Illness This Holiday Season with Tips from UTHealth ExpertsNovember 9th, 2017
UTHealth Study Paves the Way for Clostridium Difficile Treatment in Pill FormMarch 14th, 2017
Join now to see all

Grant Support

Infectivity Of Cryptosporidium Parvum For Adult HumansNational Center For Research Resources1994–1997
Study Of The Pathogenesis Of Aeromonas Hydrophila Enteroadherent E. Coli In ManNational Center For Research Resources1985